Post by Helena Smolak

DOUBLE-SCOOP: Eli Lilly and Company, Boehringer Ingelheim significantly withdraw investment from Germany - First to report that Boehringer Ingelheim cut its 900 million euro #investment in Germany. The family-owned drugmaker confirmed this to Handelsblatt upon request. Shortly after, we reported that Eli Lilly is halving its 2.3 billion euro commitment to the country. - CEO of the trillion-dollar market cap weight-loss drugmaker Dave Ricks typically doesn’t do virtual interviews. Yesterday he did. "Germany will fall to last place among European markets in supporting our industry," Ricks told me. The investments pulled from Germany are now likely to go to Pennsylvania in the US – or to an entirely new location that would first have to be built, Ricks said. Two news amid a political debate that couldn't be more timely. Reason is Nina Warken's planned austerity package - which goes into its first reading next week. Will this trigger a renewed debate in Berlin? Share your take in the comments. With Britta Rybicki and support of the team to bring both stories online fast.